EVOK — Evoke Pharma Income Statement
0.000.00%
Last trade - 00:00- $3.85m
- -$4.75m
- $10.25m
Annual income statement for Evoke Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.023 | 1.62 | 2.51 | 5.18 | 10.2 |
| Cost of Revenue | |||||
| Gross Profit | -0.064 | 1.29 | 2.14 | 4.98 | 9.89 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 13.1 | 9.77 | 10.3 | 12.6 | 15.5 |
| Operating Profit | -13 | -8.15 | -7.79 | -7.43 | -5.2 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -13.2 | -8.54 | -8.22 | -7.79 | -5.35 |
| Net Income After Taxes | -13.2 | -8.54 | -8.22 | -7.79 | -5.35 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -13.2 | -8.54 | -8.22 | -7.79 | -5.35 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -13.2 | -8.54 | -8.22 | -7.79 | -5.35 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -74.3 | -38.2 | -31.4 | -28 | -2.81 |